TD Cowen downgraded Exscientia to Hold from Buy without a price target following the proposed merger with Recursion. The firm believes a higher bid is unlikely and expects the deal should close by early 2025 as expected.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAI:
- Exscientia price target lowered to $9 from $10 at Barclays
- Exscientia Secures Full Rights to Novel Cancer Drug
- Exscientia pays GT Apeiron $10M upfont cash+ equity for ‘full control’ of 617
- Exscientia launches AWS AI-powered platform to advance drug discovery
- Exscientia initiated with a Buy at TD Cowen